-
A5413: Dasatinib for HIV-1 Reservoir Reduction
To determine if dasatinib is safe and well tolerated in people with HIV, and to see if dasatinib can reduce…
Open and enrolling
HIV Cure, Treatment Experienced
36 weeks
- Study Treatment: 12 Weeks
- Follow-up: 24 Weeks
-
A5428: Small Trial of Alendronate Impact on the Reservoir of HIV (STAIR-HIV)
Though antiretroviral therapy (ART) is very effective at suppressing the HIV virus, it is, however, unable to totally remove it…
Open and enrolling
HIV Cure, Treatment Experienced
Participants will be in this study for about 44 weeks; this includes:
- 12 weeks for pre-intervention evaluations
- 24 weeks of study treatment
- 8 weeks of follow-up after stopping study treatment
-
A5389: Two bNAb Combination for Acute HIV-1 Infection
This study will evaluate the combination of two experimental broadly neutralizing antibodies (bNAbs) in participants who started anti-HIV medications (also…
Active, Not Recruiting
HIV Cure, Treatment Experienced
The maximum time you will be in the study is about 98 weeks.
-
ACTG TO MAKE THREE PRESENTATIONS ON HIV CURE AND AGING WITH HIV AT AIDS 2026
ACTG, a global clinical trials network focused on HIV and other infectious diseases, announced today that it will make three…
Jul 29, 2026
-
ACTG LAUNCHES HIV CURE STUDY EVALUATING NOVEL APPROACH TARGETING THE HIV RESERVOIR
ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the recent opening of study…
Jun 03, 2026
-
ACTG LAUNCHES SECOND HIV CURE CLINICAL TRIAL IN AFRICA
Jan 21, 2025
-
ACTG ANNOUNCES LAUNCH OF ITS FIRST HIV CURE CLINICAL TRIAL IN AFRICA
Jul 16, 2024
-
Study will enroll participants who initiated treatment shortly after acquiring HIV
Apr 22, 2024
-
A5341s: A5321 Sampling Substudy Longitudinal Sampling Substudy of A5321 is collecting information from measures of different HIV reservoirs, including…
Closed to accrual
HIV Cure
-
Will evaluate whether starting antiretroviral drugs very early in HIV infection will limit the virus from getting into hidden areas…
Closed to accrual
HIV Cure
The duration of the study is up to 72 weeks (a year and a half).
-
A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term ART
AHRC (pronounced “ARC”) is a study of differences and changes over time in HIV reservoirs (groups of HIV-infected cells that…
Closed to accrual
HIV Cure, Treatment Experienced
Participants will be expected to stay in the study for about 7 years.
-
Designed to develop a standard operating procedure to establish a storage bank for specimens for future HIV DNA analyses. Informed…
Closed to accrual
Hepatitis, HIV comorbidities and complications, HIV Cure, HIV Treatment, Tuberculosis